Sanofi ups outlook; tech sell-off hits Europe

(AWP Alliance News) - The following stocks are the leading risers and fallers in Europe's major stock indices on Friday.

----------

CAC 40 WINNERS

----------

Sanofi SA, up 4.6% at EUR79.67, ups guidance

----------

EssilorLuxottica SA, up 2.9% at EUR183.35

----------

Danone SA, up 2.6% at EUR66.04

----------

CAC 40 LOSERS

----------

Stellantis NV, down 3.7% at EUR4.07

----------

STMicroelectronics NV, down 3.6% at EUR42.64

----------

Schneider Electric SE, down 3.0% at EUR240.10, falls amid data centre exposure as artificial intelligence sector sentiment hit again

----------

DAX 40 WINNERS

----------

Bayer AG, up 4.0% at EUR49.86

----------

Beiersdorf AG, up 3.3% at EUR83.46

----------

Henkel AG & Co KGaA, up 2.2% at EUR80.42

----------

DAX 40 LOSERS

----------

Siemens Energy AG, down 5.7% at EUR128.48

----------

Infineon Technologies AG, down 4.2% at EUR51.74, semiconductor shares hit by AI worry

----------

Deutsche Bank AG, down 2.7% at EUR30.32

----------

FTSE 100 WINNERS

----------

BT Group PLC, up 5.4% at 224.55p, broadband rival in talks to use firm's fibre network

----------

AstraZeneca PLC, up 4.0% at 13,573.00p, better than expected revenue

----------

Relx PLC, up 3.0% at 3,001.50p

----------

FTSE 100 LOSERS

----------

NatWest Group PLC, down 6.9% at 591.20p, weaker than forecast net interest income

----------

Polar Capital Technology Trust PLC, down 4.5% at 601.50p, hit by tech share sell-off

----------

Airtel Africa PLC, down 4.2% at 262.70p

----------

MIB 40 WINNERS

----------

Campari NV, up 1.6% at EUR6.23

----------

Moncler Spa, up 1.6% at EUR42.79

----------

Inwit Spa, up 1.3% at EUR7.38

----------

MIB 40 LOSERS

----------

Amplifon Spa, down 14% at EUR11.29, lack of guidance hike hits shares

----------

Technoprobe Spa, down 7.0% at EUR24.74

----------

Prysmian Spa, down 4.8% at EUR109.40

----------

SMI 20 WINNERS

----------

Givaudan SA, up 2.0% at CHF3,994.00

----------

Nestle SA, up 1.8% at CHF84.31

----------

Swiss Re AG, up 1.5% at CHF153.15

----------

SMI 20 LOSERS

----------

Logitech International SA, down 3.9% at CHF78.50

----------

ABB Ltd, down 2.5% at CHF71.30

----------

UBS Group AG, down 1.5% at CHF39.13

----------

European stock movers in focus:

----------

BT Group, up 5.4% at 224.55p, 12-month range 173.00p-242.09p. The Financial Times reports Virgin Media O2 is nearing a deal to use BT's fibre broadband network, halting upgrade plans of its own. Citing people familiar with the matter, the Financial Times reports VMO2 will use Openreach for new customers in area not covered by its own existing network. VMO2, co-owned by Telefonica SA and Liberty Global Ltd, is one of BT's biggest UK broadband rivals.

----------

Sanofi, up 4.6% at EUR79.67, 12-month range EUR69.75-EUR90.79. Shares climb as the pharmaceutical firm lifts its annual guidance and reports double-digit third quarter sales growth on strong demand for its Dupixent treatment. Sanofi now expects annual sales growth in the low teens at constant currency, raised from around 10% previously. Business earnings per share are to grow by a mid-teens percentage, compared with its previous forecast for growth slightly faster than sales.

----------

Infineon Technologies, down 4.2% at EUR51.74, 12-month range EUR31.27-EUR88.83. Shares in the semiconductor manufacturer are hit by as sentiment towards stocks with an artificial intelligence sector exposure takes a dive again. At the heart of the sell-off, Amazon.com Inc is down 6.7% in pre-market trade in New York. "Amazon delivered strong cloud growth, and revenues climbed 12% YoY, however, earnings per share was weaker than expected, and free cash flow turned negative to the tune of USD42.4 billion, due in part to its USD220 billion AI spend. Considering its main AI unit, Amazon Web Services, generated USD46 billion in revenues last quarter, the cost of Amazon's AI ambitions is not yet justified by sales, even though AWS sales growth is rising at a fast pace," XTB analyst Kathleen Brooks comments.

----------

AstraZeneca, up 4.0% at 13,573.00p, 12-month range 9,892.00p-15,732.00p. The drugmaker posts strong third quarter results with sales ahead of forecast. Pretax profit rises 22% to USD3.96 billion in the third quarter ended September 30 from USD3.24 billion a year earlier. Revenue increases 6.7% to USD16.21 billion from USD15.19 billion, beating USD15.94 billion company compiled consensus by 1.7%.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom [at] alliancenews.com